Please login to the form below

Not currently logged in
Email:
Password:

biologic

This page shows the latest biologic news and features for those working in and with pharma, biotech and healthcare.

FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics

FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics

Biologic manufacturers have a right to defend their legitimate intellectual property interests, and we want them to continue to offer the benefits of improved versions of originator biologics, ”said Gottlieb. ... the same tactics, and all of us being

Latest news

More from news
Approximately 19 fully matching, plus 562 partially matching documents found.

Latest Intelligence

  • Mylan sees the UK paving the way for an insulin game changer Mylan sees the UK paving the way for an insulin game changer

    4th generation of biologics.

  • ‘How is your day?’ ‘How is your day?’

    Plasma protein therapies are biologic medicines – derived from human plasma or recombinant analogues (that treat bleeding disorders) – that treat a range of life-threatening, chronic and genetic diseases.

  • Leo has its eyes on the prize Leo has its eyes on the prize

    Advancing biologics and adding biomarkers for precision medicine is one of the steps we are going to see in the coming years. ... We have multiple approaches such as combining biologics where we may be able to address the inflamation and itch while

  • Deal Watch January 2018

    Jill Ogden has over 30 years of commercial and R&D experience in the biopharmaceuticals and healthcare industries and provides our biologics, early stage deals and platform technologies expertise.

  • The good, the bad and the ugly The good, the bad and the ugly

    Humira is entrenched as a first-line biologic for the treatment of numerous conditions - and despite the EU launch of biosimilars in 2018, we anticipate that it will remain a ... Its revenues grew by a further 9% last year. “A large percentage of this

More from intelligence
Approximately 2 fully matching, plus 65 partially matching documents found.

Latest appointments

More from appointments
Approximately 7 fully matching, plus 43 partially matching documents found.

Latest from PMHub

  • It’s all about patient outcomes… right?

    a novel biologic agent. ... Consequently, the roll-out of the novel biologic agent was conducted in a manner that was sensitive to the PCP/specialist interaction observed, ensured smooth communications and optimised patient outcomes.

  • Biotech: it's a people business

    Biologic therapies have become a central part of modern day medicine and a key part of biotech and pharma portfolios.

  • Webcast: Biosimilars: Friend or Foe to Healthcare?

    Webcast: Biosimilars: Friend or Foe to Healthcare? Understanding the opportunities for biosimilars and the threats to innovator biologics. ... Gain greater insight into what companies entering the market need to do to effectively launch their follow-on

  • Infographic: RA Perceptions

    Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’ s RoActemra) are expected to outperform the overall EU biologics market ... Biosimilars (the approved follow-on

  • Biosimilars: Getting the flock to market

    originator biologic agent, offering comparable efficacy and safety but with a lower acquisition cost. ... So biosimilars not only increase patient access to tried and trusted biologics, they may accelerate adoption of new agents.

More from PMHub
Approximately 7 fully matching, plus 41 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

Transforming healthcare through effective collaboration. Making work to feel proud of. www.dovetailstrategies.com...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics